Pharmacokinetic/Pharmacodynamic of Albinterferon Alfa-2b in Chronic Hepatitis B, eAg+, Infection Subjects
Status:
Terminated
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
This study will assess the efficacy of ABF656 in chronic hepatitis B characterized by HBeAg
positivity. The study is designed to establish a dose response and safety relationship
sufficient to allow the subsequent design and conduct of Phase 3 trials. The trial is also
designed to generate the PK data in hepatitis B patients to satisfy regulatory requirements
in China.